Price
No data yet.
Social Signal Score
Revenue
$235.0K+267.19%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Angulo
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 18
- Beta
- 1.10
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -4.31
Financials
Revenue
$235.0K+267.2%Net Income
$7.40MEBITDA
$7.40MFree Cash Flow
$-14.88MEPS (diluted)
$0.63Shares Outstanding (diluted)
11.82M+404.8%Operating Expenses
$8.01MCash & Debt
$54.08MReturn of Capital
$2.54MRevenue by Segment (annual)
$20.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $20.60M | $-8.61M | $-1.38 |
| 2024 | $3.75M | $-21.29M | $-3.51 |
| 2023 | $140.14M | $67.04M | $11.21 |
| 2022 | $5.09M | $-62.81M | $-11.79 |
| 2021 | $13.16M | $-32.87M | $-9.97 |
| 2020 | $0.00 | $-55.19M | $-41.18 |
| 2019 | $121.0K | $-53.71M | $-76.62 |
| 2018 | $257.0K | $-12.47M | $-22.73 |
| 2017 | $257.0K | $-25.06M | $-75.20 |
| 2016 | $257.0K | $-29.99M | $-126.04 |
| 2015 | $257.0K | $-32.62M | $-214.08 |
| 2014 | $1.26M | $-4.23M | $-83.20 |
| 2013 | $16.86M | $-30.46M | $-1136.00 |
| 2012 | $16.84M | $-11.48M | $-580.80 |
Valuation
SCYXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
SCYNEXIS to Participate in Upcoming Investor Conferences JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced that the company will participate in the following investor conferences:
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat diseases with significant unmet medical need, today announced the grant of an inducement equity award to a new Senior Director, with a grant date of August 24, 2026. The award was granted in connection with the commencement of …
View source ↗
Earnings
Wed, Nov 4(in 2 months)
Consensus estimate $-0.72 per share
Typical surprise +26.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$0.63 vs $-0.51beat
- Mon, May 11$-3.36 vs $-0.80miss
- Wed, Mar 4$2.00 vs $1.01beat
- Wed, Nov 5$-1.36 vs $-1.60beat
- Thu, Aug 14$-1.12 vs $-1.52beat
- Fri, May 16$-0.88 vs $-1.55beat
Estimates and results for SCYX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SCYX officers and directors.
- Bought
- $393k
- Sold
- —
5 trades
0 trades
- Angulo Gonzalez Davidbought
- Angulo Gonzalez Davidbought
- Angulo Gonzalez Davidbought
- Taglietti Marcobought
- Sukenick Scottbought
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.